Europe Sugar Based Excipients Market By Type (Powders and Granules, Crystal, Syrup And Others), Product (Actual Sugar, Sugar Alcohol And Artificial Sweeteners), Functionality (Filler, Diluent, Flavouring Agent And Tonicity Agent), Formulation (Oral, Topical And Parenteral), And Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) – Size, Share, Trends, Growth, Forecast (2025 to 2033)
The size of the Europe Sugar-Based Excipients Market was calculated to be USD 278.65 million in 2024 and is anticipated to be worth USD 395.89 million by 2033, from USD 289.75 million in 2025, growing at a CAGR of 3.98% during the forecast period.
Sugar-based excipients refer to inactive substances derived primarily from sucrose, lactose, and other carbohydrate sources that serve as fillers, binders, stabilizers, or diluents in pharmaceutical formulations. In Europe, these excipients are integral to solid oral dosage forms, leveraging their compressibility, solubility, and compatibility with active pharmaceutical ingredients. The European market operates within a tightly regulated framework governed by the European Pharmacopoeia and stringent quality standards enforced by the European Medicines Agency. According to a European Parliament report, oral solid dosage forms constitute a significant majority of the market (often cited as over two-thirds or roughly 60-70%) of medicines produced, many of which incorporate sugar-based excipients. As per the Eurostat data for 2023, the EU produced 2.9 million tonnes of dairy powder products, with this production coming from 19.2 million tonnes of skimmed milk and 5.1 million tonnes of whole milk. The region’s well-established dairy infrastructure, particularly in Germany, France, and the Netherlands, provides a consistent and high-purity feedstock for excipient manufacturing. According to USDA data for 2024/2025, the European Union (EU-27) accounts for approximately 22% of the global dairy output. Europe is still a significant producer and major exporter of high-value dairy products, providing a strategic advantage in the supply chain for dairy-derived excipients. This robust agro-industrial ecosystem, combined with Europe’s leadership in generic and specialty pharmaceuticals, underpins the sustained relevance of sugar-based excipients across the continent’s healthcare value chain.
The overwhelming preference for solid oral dosage forms across the regional healthcare systems continues to be a vital accelerator for the Europe sugar-based excipients market. According to data from the European Generic Medicines Association, solid forms such as tablets and capsules represented a significant share of all pharmaceutical units dispensed in the European Union. These formulations rely heavily on excipients like lactose monohydrate and sucrose for their functional properties, including flowability, compactability, and stability. Lactose constitutes a key portion of all filler binders used in oral solid dose manufacturing in Europe, as per an industry analysis by the European Federation of Pharmaceutical Industries and Associations. The extensive use of generic drugs in public health systems further amplifies this demand, with generics accounting for a portion of all prescriptions in Germany and similar levels in France and Italy. Moreover, regulatory alignment across the EU ensures that excipients meeting European Pharmacopoeia standards are readily accepted, enabling seamless integration into manufacturing pipelines. The rise in chronic disease prevalence also contributes, with the World Health Organization (WHO) estimating that non-communicable diseases (NCDs) are responsible for approximately 80% to 90% of total deaths in the WHO European Region, a higher proportion than the global average of 71%. Consequently, the structural reliance on tablet-based treatments in both public and private healthcare settings sustains consistent demand for high-quality sugar-based excipients across the continent.
The demographic shift toward an aging population, coupled with heightened focus on pediatric drug development, has intensified demand for palatable and easily administrable formulations, which directly benefits the expansion of the Europe sugar-based excipients market. As per research, the portion of people in the European Union who are 65 or older is growing steadily and is expected to become a larger part of the total population in the near future. This aging cohort often requires medications with enhanced swallowability and taste masking capabilities, characteristics effectively delivered by sucrose and lactose-based matrices. Simultaneously, the European Union has a regulation in place to encourage the development of medicines specifically for children, a framework that has been successful in approving many new treatments since it was introduced. Many of these formulations utilize sugar-based excipients to improve compliance through better taste and texture. Besides, orodispersible tablets and chewable dosage forms depend extensively on sugar derivatives for rapid disintegration and pleasant mouthfeel. These demographic and regulatory dynamics collectively reinforce the indispensable role of sugar-based excipients in next-generation patient-centric drug delivery.
The European regulatory environment imposes rigorous quality and traceability requirements on pharmaceutical excipients, which creates significant compliance barriers for the Europe sugar-based excipients market. The European Medicines Agency mandates that all excipients used in human medicines must comply with the European Pharmacopoeia monographs, which specify strict limits for impurities including residual solvents, heavy metals, and microbial contamination. Manufacturers must implement full supply chain transparency, often requiring certification of non-animal origin or verification of dairy processing methods. This is particularly challenging for lactose derived from whey, a byproduct of cheese manufacturing, where cross-contamination risks and inconsistent purity levels can arise. Further complicating matters, the EU’s Falsified Medicines Directive requires unique identifier serialization for all medicines, indirectly pressuring excipient suppliers to ensure batch-level consistency. These regulatory complexities increase production costs and lead times, especially for small to mid-sized excipient producers who lack the infrastructure for comprehensive quality assurance systems, thereby constraining market entry and innovation in sugar-based excipient development.
The rising availability and adoption of synthetic or chemically modified excipients pose a major restraint to the Europe sugar-based excipients market. Cellulose derivatives such as microcrystalline cellulose and synthetic polymers like polyvinylpyrrolidone offer enhanced functional properties, including superior moisture resistance, higher compressibility, and greater stability in humid environments, attributes particularly valuable in Southern and Eastern European climates. According to a study, the use of non-saccharide excipients in solid oral formulations increased, driven by formulators seeking consistent performance across diverse storage conditions. Apart from these, the prevalence of lactose intolerance is consistently high (affecting a notable percentage of adults) in Southern Europe, and this widespread occurrence has prompted the food and pharmaceutical industries to reformulate products using lactose-free alternatives. Companies have publicly announced lactose reduction initiatives in their European product portfolios to broaden patient accessibility. Moreover, advances in excipient engineering have led to multifunctional co-processed blends that combine disintegration, binding, and flow enhancement in a single component, reducing reliance on simple sugars. These technological and clinical shifts collectively erode the market share of conventional sugar-based excipients, which compels suppliers to invest in innovation or risk obsolescence in an increasingly performance-driven pharmaceutical landscape.
The ongoing transition from batch to continuous manufacturing in the region’s pharmaceutical sector offers a key opportunity for the Europe sugar-based excipients market. Continuous manufacturing improves efficiency, reduces waste, and enhances product consistency, objectives strongly supported by the European Medicines Agency’s regulatory encouragement since 2020. According to the European Federation of Pharmaceutical Industries and Associations’ 2024 publications, the research-based pharmaceutical industry is actively investing in innovative manufacturing technologies, including continuous processing, as a key part of its strategy to improve supply reliability and adopt digital and green transitions. These systems demand excipients with highly uniform particle size distribution, excellent flow properties, and minimal variability —characteristics that modern spray-dried lactose and co-processed sucrose derivatives can fulfill. Companies such as Roquette and DFE Pharma have already introduced tailored sugar-based excipients designed specifically for continuous direct compression, a method that bypasses granulation and relies entirely on excipient performance. The reduced solvent use and energy consumption inherent in continuous systems align well with the sustainability goals of the EU's Green Deal, which promotes resource-efficient manufacturing. This technological shift creates a niche yet high-value market for next-generation sugar-based excipients that meet the exacting standards of real-time production environments by offering suppliers a strategic avenue for premium product differentiation and long-term partnerships with leading drug manufacturers.
The accelerated development of orphan drugs and personalized therapies in Europe is generating specialized demand for high-purity and flexible excipients suitable for low volume and high potency formulations, which ultimately provides fresh prospects for the expansion of the Europe sugar-based excipients market. The European Medicines Agency has granted a high number of new orphan drug designations, leading to an increasing number of these specialized medicines becoming available for use across the EU market. These therapies often require minimal dosing and specialized delivery formats such as orodispersible films or mini tablets, where sugar excipients play a crucial role in achieving precise drug loading and rapid dissolution. Besides, the rise of hospital-based compounding pharmacies—regulated under the EU Falsified Medicines Directive—has increased the need for pharma-grade lactose and sucrose that can be reliably used in small-scale, customized preparations. According to research, many hospital pharmacies in the EU frequently compound oral solid doses, with most identifying specific taste-masking components as crucial for elderly and child patients. Furthermore, Significant financial investment has been directed through the EU’s Innovative Medicines Initiative towards research and development projects in the field of personalized medicine over the last few years. These niche but high margin segments require excipients that meet stringent pharmacopeial standards while offering functional versatility, conditions under which high purity, spray-dried lactose, and directly compressible sucrose excel. This convergence of regulatory support, clinical need, and technological innovation positions sugar-based excipients as critical enablers in Europe’s evolving precision medicine ecosystem.
The dependence of these excipients on dairy byproducts, particularly whey from cheese production, exposes them to significant supply chain volatility and hinders the growth of the Europe sugar-based excipients market. This is driven by agricultural market fluctuations and climate-related disruptions. Lactose, the most widely used sugar-based excipient, is extracted from whey, a byproduct of the cheese industry, which itself is subject to seasonal variations, milk quota adjustments, and global commodity pricing. Moreover, the EU’s Common Agricultural Policy reforms and environmental regulations limiting herd sizes in the Netherlands and Denmark further constrain long-term whey supply. Since a large part of European lactose-based excipients originates from dairy streams, any instability in milk collection or cheese manufacturing cascades directly into excipient production. This raw material dependency creates pricing unpredictability and inventory challenges for pharmaceutical formulators who require consistent excipient quality for regulatory compliance. Until alternative non-dairy fermentation routes achieve commercial scale, a prospect still limited by high production costs, the sector remains vulnerable to agro-climatic and policy-driven disruptions that threaten supply continuity and cost stability.
Conventional sugar-based excipients such as standard lactose monohydrate and crystalline sucrose exhibit functional limitations that hinder their adoption in advanced drug delivery systems, and pose a persistent challenge for the Europe sugar-based excipients market growth. These materials often lack the mechanical strength, moisture resistance, and flow characteristics required for high-speed tablet presses or moisture-sensitive active ingredients. According to a study, a share of European formulation scientists reported encountering compaction or capping issues when using unmodified lactose in high-dose or low-bulk-density formulations. Although co-processed or spray-dried variants exist, their development has lagged behind synthetic alternatives due to limited investment in excipient R&D by European raw material suppliers. As per research, a smaller share of pharmaceutical materials innovation grants between 2021 and 2024 targeted carbohydrate-based excipient modification. This underinvestment contrasts sharply with the rapid advancement of cellulose and polymer-based systems that offer tunable release profiles and enhanced stability. Consequently, many European generic manufacturers default to imported or synthetic options for complex formulations, which reduces the strategic relevance of domestic sugar-based excipients. In an increasingly sophisticated pharmaceutical manufacturing environment that prioritizes performance, traditional sugars could be relegated to commodity status unless there is focused innovation in particle engineering, surface modification, or hybrid excipient design.
| REPORT METRIC | DETAILS |
| Market Size Available | 2024 to 2033 |
| Base Year | 2024 |
| Forecast Period | 2025 to 2033 |
| CAGR | 3.98% |
| Segments Covered | By Type, Product, Functionality, Formulation, And Region |
| Various Analyses Covered | Global, Regional & Country Level Analysis; Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Regions Covered | North America, Europe, APAC, Latin America, Middle East & Africa |
| Market Leaders Profiled | Lubrizol Corporation, Archer Daniels Midland Company, Roquette Group, Ashland Inc., Meggle AG, Associated British Foods Plc, FMC Corporation, BASF SE, Dfe Pharma, Cargill, Inc., and Colorcon |
The powders and granules segment was the largest segment in the Europe sugar-based excipients market by accounting for a 63.2% share in 2024. The dominance of the powders and granules segment is attributable to its optimal compatibility with direct compression and roller compaction processes widely used in solid oral dosage manufacturing across the region. The segment also benefits from high solubility, excellent mixing homogeneity, and ease of handling in automated tablet presses, features critical for high-throughput facilities in Germany and France. Besides, major excipient producers such as DFE Pharma and Roquette have invested heavily in co-processed powder technologies that combine lactose with cellulose or starch derivatives to enhance functionality while maintaining regulatory compliance. As per sources, the EU’s pharmaceutical production index rose, driven largely by increased output of generic tablets, which further solidified demand for powder and granule formats. Their adaptability to moisture-controlled environments and scalability across batch and continuous manufacturing systems reinforce their entrenched position in European formulation pipelines.
The syrup segment is anticipated to witness the fastest CAGR of 7.1% between 2025 and 2033. The rapid expansion of the syrup segment is primarily fuelled by rising demand for liquid pediatric formulations and geriatric oral suspensions that prioritize palatability and precise dosing. According to research, liquid oral medicines accounted for a portion of pediatric drug authorizations issued, many of which rely on sucrose or sorbitol syrups as both sweetening and stabilizing agents. The format’s inherent advantages, such as rapid dissolution, dose flexibility, and absence of swallowing barriers, make it indispensable in age-specific therapeutic areas. Furthermore, hospital pharmacies across the EU are increasingly compounding customized syrups for rare disease treatments, with an increase in liquid formulation. Regulatory alignment under the EU Paediatric Regulation has also incentivized syrup development by granting extended market exclusivity for age-appropriate medicines. This segment is set for sustained expansion due to innovations in preservative-free syrup stabilization by companies such as Cargill and Ingredion, a trend that coincides with Europe’s healthcare system progressively adopting more patient-centric delivery models.
The actual sugar segment captured a substantial share of the Europe sugar-based excipients market in 2024. The expansion of the actual sugar segment is driven by its established regulatory acceptance, cost efficiency, and functional versatility in solid dosage forms. Lactose constitutes a significant share of the actual sugar excipient category, sourced largely from the EU’s robust dairy sector. According to Eurostat data, the European Union (EU) produced an estimated 160.8 million metric tons of raw milk in 2023, generating abundant whey streams for high-purity lactose extraction. The European Pharmacopoeia’s longstanding monographs for lactose ensure seamless integration into GMP-compliant manufacturing, reducing qualification burdens for pharmaceutical firms. Moreover, actual sugar excipients exhibit superior compressibility and compatibility with a wide range of active ingredients, which makes them the default choice for generic manufacturers in high-volume markets like Germany and Italy. The segment’s dominance is further supported by the absence of metabolic restrictions on lactose in non-pediatric, non-intolerance sensitive populations by allowing broad application across therapeutic categories, including cardiovascular, CNS, and anti-infectives.
The sugar alcohols segment is likely to experience the fastest CAGR of 8.3% during the forecast period, owing to its dual role as excipients and functional sweeteners in sugar-free and diabetic friendly formulations. Mannitol’s non-hygroscopic nature and excellent mouthfeel make it ideal for chewable tablets and orodispersible systems, while sorbitol serves as a stabilizer in liquid suspensions. The European Food Safety Authority has affirmed the safety of sugar alcohols in pharmaceutical applications, accelerating their adoption. Companies have responded with high-purity, pharma-grade sugar alcohol lines tailored for niche delivery systems. Europe's aging population and increasing rates of metabolic disorders are driving the need for new solutions. Sugar alcohols offer a scientifically validated and regulatory-compliant pathway to meet these evolving patient needs, underpinning their rapid market ascent.
The filler functionality segment led the Europe sugar-based excipients market and occupied a 57.4% share in 2024. The growth of the filler functionality segment is propelled by the indispensable role of sugars like lactose in providing bulk to low-dose active pharmaceutical ingredients. In oral solid dosage forms, where active compounds often constitute less than 5 percent of total tablet mass, fillers ensure mechanical integrity and consistent dosing. According to the European Directorate for the Quality of Medicines (EDQM), the European Pharmacopoeia (Ph. Eur..) contains specific individual monographs for excipients like Lactose monohydrate (0187) and Lactose, anhydrous (1061), and general monographs related to dosage forms, which underscore the regulatory entrenchment of these materials in pharmaceutical manufacturing. The dominance is further amplified by Europe’s high output of generic tablets, billions of units produced annually, most of which rely on lactose monohydrate for their compressibility and flow properties. Germany alone accounts for a notable share of EU tablet production, with major facilities operated by STADA and Ratiopharm standardized on lactose filler systems. Apart from these, the cost efficiency of sugar-based fillers makes them economically vital for public healthcare systems under budget pressure. The filler function remains the structural backbone of Europe’s solid dose pharmaceutical infrastructure because chronic diseases are increasing long-term medication use.
The flavouring agent segment is on the rise and is expected to be the fastest-growing segment in the market by witnessing a CAGR of 9.2% from 2025 to 2033 due to factors such as the EU’s intensified focus on medication adherence, particularly in pediatric and geriatric populations, where taste aversion leads to treatment discontinuation. Sucrose and other sugar derivatives serve not only as sweeteners but also as masking agents that neutralize bitter active ingredients. Regulatory initiatives further mandate taste evaluation for pediatric formulations by institutionalizing the need for effective flavouring excipients. Leading companies have developed co-processed sucrose systems that integrate flavour retention with rapid dissolution. Moreover, the rise of orodispersible tablets relies on sugar-based matrices to deliver immediate taste masking upon contact with saliva. The flavoring agent function is transitioning from ancillary to strategic because patient-centricity is now both a regulatory and a commercial necessity.
The oral segment held the leading share of the Europe sugar-based excipients market in 2024. The prominence of the oral segment is because of the entrenched preference for tablets, capsules, and liquids in European therapeutic practice. This format aligns with cost-effective manufacturing, patient self-administration, and established regulatory pathways. Sugar-based excipients like lactose and sucrose are integral to this segment due to their GRAS status, solubility, and compatibility with high-speed tableting. The EMA’s centralized procedure for generic approvals has further streamlined oral solid dose development. Germany, France, and Italy, the EU’s key pharmaceutical countries, collectively account for a notable share of oral solid dose production, relying heavily on domestic lactose supply chains. Apart from these, public reimbursement schemes in countries like Sweden and the Netherlands prioritize oral generics for chronic conditions, reinforcing volume demand. The oral segment’s dominance is not merely technological but systemic, embedded in Europe’s healthcare economics, patient behavior, and industrial infrastructure.
The parenteral formulation segment is expected to exhibit a noteworthy CAGR of 10.4% over the forecast period. While traditionally dominated by non-sugar excipients, parenteral applications are increasingly incorporating sugar derivatives like sucrose and trehalose as stabilizers for biologics and vaccines. The rise of monoclonal antibodies and recombinant proteins has intensified demand for high-purity sugars that prevent protein denaturation. Regulatory guidelines from the European Pharmacopoeia now include specific monographs for injectable grade sucrose, enabling its use in aseptic manufacturing. Furthermore, the EU’s investment in mRNA vaccine infrastructure post-pandemic has created new demand for lyophilized formulations. Companies have scaled production of endotoxin-free sucrose for parenteral use. Sugar-based excipients are becoming critically relevant beyond traditional oral routes as Europe moves toward the use of advanced therapies.
Germany was the top performer in the Europe sugar-based excipients by holding a 26.3% share in 2024. The supremacy of Germany in the regional market is attributable to a dense concentration of generic pharmaceutical manufacturers, robust dairy processing infrastructure, and a highly regulated yet innovation-friendly healthcare system. According to research, the country hosts a large number of licensed pharmaceutical production sites. The nation’s dairy industry produced millions of metric tons of milk in 2023, which ensures a steady supply of whey for excipient-grade lactose. Apart from these, Germany’s statutory health insurance system covers most of the population, driving high prescription volumes, particularly for chronic disease medications that use standardized excipient blends. Regulatory alignment with EU pharmacopoeial standards and strong investment in continuous manufacturing further strengthen Germany’s dominance. The presence of global excipient suppliers like DFE Pharma and BASF also positions the country as a formulation and distribution hub for Central and Eastern Europe.
France was the second-largest in the Europe sugar-based excipients market by capturing a 15.8% share in 2024 because of its strong public healthcare framework and command in pediatric and geriatric drug development. According to sources, a significant number of pharmaceutical units were reimbursed through the national health system. French pharmaceutical firms such as Sanofi and Servier have long standardized lactose-based formulations, leveraging domestic dairy outputs from regions like Brittany and Normandy, which collectively contribute notably to the country’s milk production. Besides, France’s regulatory emphasis on taste masking in pediatric medicines has elevated demand for sucrose syrups and co-processed granules. The country’s academic research institutions are also pioneering excipient innovation in orodispersible systems, which supports France’s strategic position in both volume and specialty segments of the market.
The United Kingdom remains a major player in the Europe sugar-based excipients market by maintaining influence despite Brexit through its advanced pharmaceutical R&D ecosystem and strong generics sector. The country’s National Health Service dispensed d substantial quantity of prescription items in 2024, which creates consistent demand for cost-effective excipients. UK-based generics manufacturers such as Teva UK and Aurobindo Pharma rely on imported bupharmacopeia-compliant sugar excipients, with supply chains increasingly localized through partnerships with European producers. The UK’s Medicines and Healthcare products Regulatory Agency continues to align with European Pharmacopoeia standards, facilitating seamless excipient qualification. Furthermore, UK universities are researching sugar-based matrices for personalized dose printing, opening new application frontiers. The UK's scientific infrastructure and large healthcare system ensure its sustained prominence in the regional excipient landscape, even though it is no longer part of the EU single market.
Italy saw a gradual expansion in the Europe sugar-based excipients market, with a large domestic generics industry and a high prevalence of chronic diseases requiring long-term oral therapy. Italian pharmaceutical companies such as Zentiva and EG have optimized their production lines for lactose-based direct compression, benefiting from cost advantages and regulatory familiarity. The country’s dairy sector, concentrated in Lombardy and Emilia Romagna, produced millions of metric tons of milk in 2023 by providing raw material for local lactose refiners. Italy’s aging population further drives demand for easy-to-swallow tablets and chewables that utilize sugar excipients for improved palatability. This combination of demographic pressure, industrial capacity, and public health structure sustains Italy’s position as a key consumption and innovation node in Southern Europe.
Spain is anticipated to grow in the Europe sugar-based excipients market between 2025 and 2033 due to its emergence as a dynamic player through its expanding generics sector and strategic focus on patient-centric formulations. According to the Spanish Agency of Medicines and Health Products, the country’s pharmaceutical production grew by 6.2 percent in 2024, with solid oral doses accounting for 81 percent of output. Spanish manufacturers such as Kern Pharma and Ferrer have increased investment in taste masked and orodispersible tablets, driving adoption of sucrose anco-processeded lactose systems. The country’s high prevalence of lactose intolerance has paradoxically spurred innovation in alternative sugar alcohols like mannitol for specialized products. Spain’s dairy output totaled a significant metric tons in 2023, with modern refineries in Galicia and Catalonia supplying pharma-grade lactose. Furthermore, Spain’s publicly funded healthcare system serves most of the population by ensuring stable prescription volumes.
The Europe sugar-based excipients market features intense competition among established players and niche suppliers, driven by stringent regulatory standards and demand for high-performance functional ingredients. Leading companies differentiate through purity, consistency, particle engineering, and regulatory documentation rather than price alone. Innovation in ico-processeded and modified sugar excipients has intensified as manufacturers seek to support advanced drug delivery systems, including continuous manufacturing and orodispersible formats. The market is moderately consolidated with a few multinational firms dominating due to integrated dairy sourcing, GMGMP-compliant facilities, and technical service capabilities. However, regional players gain traction by offering specialized grades for pediatric geriatric or biologic applications. Competitive pressure also stems from synthetic excipient alternatives compelling sugar-based suppliers to demonstrate superior functionality and compliance. As pharmaceutical manufacturers prioritize supply chain resilience and formulation simplicity, competition increasingly hinges on reliable application support and sustainability credentials across the European pharmaceutical value chain.
A few major players of the Europe sugar-based excipients market include
Key players in the Europe sugar-based excipients market employ product innovation through co-processing and particle engineering to meet evolving formulation needs. They invest in expanding production capacity with a focus on pharma-grade purity and regulatory compliance. Strategic partnerships with pharmaceutical manufacturers facilitate application-specific excipient development. Companies also enhance supply chain transparency using digital traceability and sustainable sourcing certifications. Geographic expansion into high-growth European subregions, such as Eastern Europe, strengthens market access. Continuous alignment with European Pharmacopoeia and EMA guidelines ensures rapid qualification. Additionally, firms provide technical and regulatory support services to reduce customer development timelines. These integrated strategies reinforce reliability, performance, and long-term customer retention in a highly regulated environment.
Roquette is a leading European player in the sugar-based excipients market with a strong global footprint in pharmaceutical and nutraceutical ingredient supply. Headquartered in France, the company specializes in high-purity lactose and mannitol derived from sustainable plant and dairy sources. Roquette has significantly advanced its portfolio through investments in spray-dried and co-processed excipient technologies tailored for continuous manufacturing and pediatric formulations. In recent years, the company expanded its Lestrem facility to increase pharma-grade lactose capacity and achieved multiple regulatory certifications, including EU GMP and US DMF compliance, reinforcing its role as a strategic partner for multinational drug manufacturers.
DFE Pharma is a prominent European supplier known for its innovative sugar-based excipient solutions, including lactose and sucrose variants engineered for direct compression and orodispersible systems. The company has consistently focused on application-driven development, collaborating closely with generic and branded pharmaceutical firms across Europe. DFE Pharma recently upgraded its production lines in the Netherlands to enhance particle size control and batch consistency. It also launched neco-processeded excipients that integrate flow and disintegration properties in a single component, supporting the industry’s shift toward simplified formulation design and regulatory compliance under European Pharmacopoeia standards.
Cargill Health Technologies leverages its global supply chain and deep expertise in carbohydrate science to serve the Europe sugar-based excipients market with high-quality lactose and sucrose products. The company ensures stringent quality control from raw material sourcing to final packaging, meeting pharmacopeial requirements in both Europe and North America. Cargill has strengthened its position through digital traceability initiatives and sustainability certifications for its dairy-derived excipients. Recently, the company enhanced its technical support services in Central and Eastern Europe, offering formulation guidance and regulatory documentation to accelerate customer product development timelines and ensure alignment with EU pharmaceutical manufacturing standards.
This research report on the European sugar-based excipients market has been segmented and sub-segmented based on type, product, functionality, formulation, and region.
By Type
By Product
By Functionality
By Formulation
By Region
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region